JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Search

Karyopharm Therapeutics Inc

Chiusa

SettoreSettore sanitario

5.72 -3.87

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

5.71

Massimo

5.95

Metriche Chiave

By Trading Economics

Entrata

-14M

-37M

Vendite

7.9M

38M

EPS

-4.07

Margine di Profitto

-98.215

Dipendenti

279

EBITDA

8.9M

-24M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+120.69% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

68M

102M

Apertura precedente

9.59

Chiusura precedente

5.72

Notizie sul Sentiment di mercato

By Acuity

50%

50%

154 / 373 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Karyopharm Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 nov 2025, 12:56 UTC

Utili

Berkshire's Quarterly Earnings Rise After Insurance Results Improve -- WSJ

1 nov 2025, 12:56 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

1 nov 2025, 12:20 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

1 nov 2025, 12:19 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

1 nov 2025, 08:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

1 nov 2025, 08:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

1 nov 2025, 05:00 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Berkshire Hathaway Probably Had a Stellar Quarter. Stock Buybacks Are a Wild Card. -- Barrons.com

1 nov 2025, 00:10 UTC

Utili

Trouble on The Strip -- Barrons.com

31 ott 2025, 23:09 UTC

Utili

Review & Preview: October Surprise -- Barrons.com

31 ott 2025, 22:44 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31 ott 2025, 21:25 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Pfizer Says Novo Nordisk's Metsera Bid Won't Pass Antitrust Laws -- Market Talk

31 ott 2025, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- Update

31 ott 2025, 21:12 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer Sues Metsera, Novo Nordisk, Claiming Novo Nordisk Takeover Offer Isn't Superior -- WSJ

31 ott 2025, 21:12 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31 ott 2025, 21:12 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer Seeks Order Blocking Metsera From Terminating Its Merger Deal With Pfizer -- WSJ

31 ott 2025, 20:51 UTC

Acquisizioni, Fusioni, Takeovers

Another Rare-Earth Stock Jumps on Government Deal -- Barrons.com

31 ott 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

31 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

31 ott 2025, 20:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

31 ott 2025, 20:46 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer: Files Lawsuit Against Metsera and Its Directors and Novo Nordisk for Breach of Merger Agreement

31 ott 2025, 20:22 UTC

Utili

Amazon Stock Hits New Record. What Was So Good in Its Earnings Report. -- Barrons.com

31 ott 2025, 20:02 UTC

Utili

Meta Faces a Sudden Reckoning. How Big Tech Earnings Are Reshaping the AI Race. -- Barrons.com

31 ott 2025, 19:55 UTC

Discorsi di Mercato

Crude Futures Fall for Third Straight Month -- Market Talk

31 ott 2025, 19:54 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer: FTC Granted Early Termination of Waiting Period >PFE

31 ott 2025, 19:54 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer: Receives Early Clearance From FTC for Metsera Acquisition

31 ott 2025, 19:26 UTC

Discorsi di Mercato

U.S. Natural Gas Rises on Winter Outlook, Strong LNG -- Market Talk

31 ott 2025, 18:30 UTC

Utili

These Stocks Are Moving the Most Today: Amazon, Nvidia, Apple, Netflix, Exxon, DexCom, Coinbase, Reddit, Newell Brands, and More -- Barrons.com

31 ott 2025, 18:23 UTC

Discorsi di Mercato

Gold Edges Lower for the Day, Closes October Positive -- Market Talk

31 ott 2025, 18:09 UTC

Utili

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31 ott 2025, 18:08 UTC

Utili

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Karyopharm Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

120.69% in crescita

Previsioni per 12 mesi

Media 12.8 USD  120.69%

Alto 21 USD

Basso 6 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Karyopharm Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

5

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

5.9501 / 7.66Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

No Evidence

Sentiment

By Acuity

154 / 373 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

help-icon Live chat